SOURCE: Cleveland BioLabs, Inc.

August 13, 2008 08:30 ET

Cleveland BioLabs and Cleveland Clinic Demonstrate Accelerated Recovery of Limb Function With Protectan CBLB502 in Tourniquet Injury Model

Potential Application for Battlefield and Natural Disaster Conditions

BUFFALO, NY--(Marketwire - August 13, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) and founding partner Cleveland Clinic reported today that CBLI's lead product, Protectan CBLB502, currently being developed as a radioprotectant and radiomitigator, demonstrated efficacy in animal models of tourniquet injury. This finding is the result of pre-clinical studies funded by a grant from the Department of Defense to research the use of Protectans in tourniquet and other ligation-reperfusion battlefield injuries, where blood flow is stopped and then restored after a prolonged period of time.

Tourniquet injury is also frequently associated with natural disaster conditions, as well as during other situations involving limb wounds or trauma. This injury is caused by prolonged deficit of oxygen supply, or ischemia, followed by rapid onset of oxidative stress at the time of tourniquet removal and results in irreversible tissue damage. Such damage often necessitates amputation of the limbs, which has restricted the use of this otherwise life saving device.

"The effect of CBLI's compound on limb recovery in our animal model of tourniquet-induced injury is encouraging and the efficacy with which it protects warrants continued investigation," said Robert Fairchild, Ph.D., of Cleveland Clinic's Lerner Research Institute. "These results will allow us to project the potential use of this compound for multiple applications beyond tourniquet injury -- from kidney and heart ischemia to reducing the rapid inflammation normally observed in transplanted organs, exploring all situations with similar mechanisms of tissue injury."

In an animal model of tourniquet-mediated limb injury simulating the situation occurring in humans, it has been demonstrated that injection of Protectan CBLB502 within 30 minutes of tourniquet removal leads to a marked reduction in the severity of injury, including reductions in tissue edema, pro-inflammatory cytokine production and leukocyte infiltration leading to accelerated recovery of limb function.

"The fact that Protectan CBLB502 demonstrated results even after the removal of a tourniquet, could make it particularly practical for battlefield conditions or other types of civilian emergency use, since it can be applied after an injured subject is delivered to the site of treatment," said Andrei Gudkov, Ph.D, D. Sci., Chief Scientific Officer of Cleveland BioLabs and inventor of the technology.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at http://www.cbiolabs.com.

The Cleveland Clinic ("CC") holds a minority equity ownership interest in Cleveland BioLabs Medical, Inc. ("Cleveland BioLabs"), and has the right to receive royalties from Cleveland BioLabs. Certain CC officials serve on the Cleveland BioLabs Board of Directors. Institutional and individual conflicts of interest in research are disclosed to, and reviewed and managed by, CC's Conflicts of Interest Committee and are subject to approval by CC's Institutional Review Board and/or Institutional Animal Care and Use Committee.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's periodic filings with the Securities and Exchange Commission.

Contact Information

  • Contact:
    Rachel Levine
    Director Corporate Development & Communications
    Cleveland BioLabs, Inc.
    T: (646) 284-9439
    E: rlevine@cbiolabs.com